|
|
|
02.03.26 - 18:54
|
Börsenradio Schlussbericht, Mo., 02.03.2026 "Sicherer Hafen"-Reflex funktioniert, Iran-Krieg schickt Öl hoch, Risiko runter (BRN)
|
|
|
Der Iran-Krieg bremst Europas Börsen über Öl und Lieferketten: Der DAX schließt bei 24.672,40 Punkten mit -2,42 %, Tagestief 24.577,42. Auch der Euro Stoxx 50 verliert -2,44 % auf 5.988,46. Verkauft werden vor allem Reise und zyklische Werte: TUI -9,90 %, Lufthansa -5,22 %, Banken ebenfalls schwach. Der Dollar wird als sicherer Hafen gesucht, EUR/USD fällt auf ca. 1,1688. Gold steigt, der Blick bleibt aber auf Öl: Brent sprang zum Wochenstart zeitweise um bis zu 13 % nach oben. In den USA startet die Wall Street klar schwächer, erholt sich aber, der S&P 500 liegt am späten Vormittag fast unverändert bei rund 6.878 Punkten. Firmen: Xeris Biopharma hebt die Umsatzprognose für 2026 auf 375 bis 390 Mio. USD, die Aktie springt vorbörslich +8,5% auf 6,64 USD. Die SNB droht wegen Frankenstärke mit Devisenmarktinterventionen. Rohstoffe: Gold um 18:00 Uhr 5.293,34 USD, +15,23 USD, +0,29 %. Schlussweisheit: "Die Börse hat neun von fünf Rezessionen vorhergesagt." - Paul Samuelson....
|
|
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 13:06
|
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance (Business Wire)
|
|
|
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively
Provides full year 2026 total revenue guidance range of $375 million to $390 million
Hosts conference call and webcast today at 8:30 a.m. ETCHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026.
"Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record revenue growth, and our emergence as a self-funding, sustainable biopharmaceutical company,” said John Shannon, CEO. “As we enter 2026 from this position of strength, we remain focused on driving continued rapid revenue growth, the timely execution of XP-8121's ongoing develo...
|
|
|
|
|
|
|
17.02.26 - 13:36
|
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 (Business Wire)
|
|
|
Conference Call to be Held at 8:30 a.m. ETCHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results.
To pre-register for the call, please go to the following link:
https://events.q4inc.com/analyst/428274643?pwd=TZMrH35H
After pre-registering, a confirmation email will be sent. To join the live webcast, please visit “Events” on the Investor Relations page, or use this link: https://events.q4inc.com/attendee/428274643. The Company recommends registering a minimum of ten minutes prior to the start of the call. A repla...
|
|
|
|
|
|
|
|
|
|
|
|
|
02.01.26 - 22:18
|
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 181,550 shares of its common stock to 50 new employee(s) under Xeris' Inducement Equity Plan.
Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees' continued employment with Xeris or one of its subsidiaries. All equity awards...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
